impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Expression of Galectin-9 and correlation with disease activity and vascular endothelial growth factor in rheumatoid arthritis

1, 2, 3, 4, 5, 6, 7, 8

 

  1. Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, and Department of Rheumatology, Qilu Hospital of Shandong University, Ji’nan, Shandong, China.
  2. Department of Rheumatology, Qilu Hospital of Shandong University, Ji’nan, Shandong, and Shenzhen Research Institute of Shandong University, Shenzhen, Guangdong, China.
  3. Department of Rheumatology, Qilu Hospital of Shandong University, Ji’nan, Shandong, and Department of Nephrology and Immunology, Shandong Provincial Third Hospital, Ji’nan, Shandong, China.
  4. Department of Rheumatology, Qilu Hospital of Shandong University, Ji’nan, Shandong, and Department of Rheumatology and Immunology, Yantai Mountain Hospital, Yantai, Shandong, China.
  5. Shenzhen Research Institute of Shandong University, Shenzhen, Guangdong, and Cryomedicine Laboratory, Qilu Hospital of Shandong University, Ji’nan, Shandong, China.
  6. Shenzhen Research Institute of Shandong University, Shenzhen, Guangdong, and Department of Haematology, Qilu Hospital of Shandong University, Ji’nan, Shandong, China.
  7. Department of Rheumatology, Qilu Hospital of Shandong University, Ji’nan, Shandong, China.
  8. Department of Rheumatology, Qilu Hospital of Shandong University, Ji’nan, Shandong, and Shenzhen Research Institute of Shandong University, Shenzhen, Guangdong, China. shuqiang@sdu.edu.cn

CER12315
2020 Vol.38, N°4
PI 0654, PF 0661
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 31820713 [PubMed]

Received: 10/04/2019
Accepted : 02/09/2019
In Press: 16/11/2019
Published: 28/07/2020

Abstract

OBJECTIVES:
Despite the important role of Galectin-9 (Gal-9) in inflammation and angiogenesis, only a few studies on Galectin-9 expression have been performed in rheumatoid arthritis (RA) patients. The present study aimed to identify the concentration of Galectin-9 in plasma, its expression in peripheral blood T cell subsets in RA patients, and the association between Galectin-9 and vascular endothelial growth factor (VEGF) in RA.
METHODS:
One hundred and five active RA patients and 52 age- and sex-matched healthy controls (HCs) were enrolled in the study. Gal-9, vascular endothelial growth factor (VEGF), and tumour necrosis factor (TNF)-α level in plasma were determined by ELISA. The intracellular positive expression rates and medium fluorescence intensity (MFI) of Gal-9 and VEGF in T cell subsets, were examined by flow cytometry.
RESULTS:
Plasma Gal-9, TNF-α, and VEGF levels were higher in the RA group than in the HCs group. The plasma Gal-9 level positively correlated with Gal-9 expression in the total lymphocyte and CD3+ T cell, CRP, SDAI, and CDAI of RA patients. The Gal-9 expressions in the cytoplasm of CD4+ T, CD8+ T, Treg, and DNT cells positively correlated with plasma TNF-α levels in RA patients. The Gal-9 expressions in CD4+ T and CD8+ T subsets also positively correlated with plasma VEGF levels. The plasma VEGF levels and VEGF expressions in CD4+ T, CD8+ T, and Treg subsets positively correlated with SDAI and CRP in RA patients.
CONCLUSIONS:
Gal-9 can be a potential biomarker for RA disease activity. Gal-9 is probably associated with angiogenesis processing in RA.

Rheumatology Article